Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sunitinib in High Risk Urothelial Carcinoma
NCT01042795Phase 2Terminated
- Sponsor
- University of Michigan
- Start
- Sep 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in urothelial carcinoma (UC), sponsored by University of Michigan. Started Sep 2009; status: terminated.
02
Drugs
sunitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01042795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01042795.